Skip to content
Brand AI

Kallyope

Request correction

Corporate brand

UnclaimedRead 2× by AI crawlers

Kallyope is a biopharmaceutical company developing innovative medicines for migraine, with a lead asset in Phase 3.

Last updated September 1, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

Kallyope is a New York City-based company focused on big health challenges, particularly migraine. It leverages unique insights into neural signaling pathways to develop innovative medicines. Its lead asset, Elismetrep, is in Phase 3 for the acute treatment of migraine. The company was founded by world-leading neuroscientists and is staffed by experienced drug developers.

History

Kallyope was founded by world-leading neuroscientists whose groundbreaking research into previously unexplored neural networks is now being carried forward by a team of experienced drug developers. The company is based in New York City and focuses on developing innovative medicines for migraine.

Recent events

  • Reported

    Kallyope appoints Patrick Flanigan as CFO[3]

    Kallyope announced that it appointed Patrick Flanigan as Chief Financial Officer.

Read more

Sources3 sources

  1. 1Kallyope | Focusing on Big Health Challenges That Matterkallyope.com
  2. 2About Us | Kallyopekallyope.com
  3. 3Kallyope任命Patrick Flanigan为首席财务官prnewswire.com

Cite this profile: Cite the canonical profile. /brand-wiki/kallyope · Editorial policy · How profiles are compiled